The effect of infliximab on oxidative stress in chronic inflammatory joint disease.
OBJECTIVE
To evaluate infliximab effect on oxidative stress in active chronic inflammatory joint disease.


METHODS
The study population comprised 12 patients: five with ankylosing spondylitis, five with rheumatoid arthritis and two with psoriatic arthritis. At the time of the study all patients were divided into two groups: (i) seven active patients and (ii) five inactive patients according to the accepted criteria that define activity of disease for each of the diseases. C-reactive protein and erythrocyte sedimentation rate were measured. Patient's Global Assessment of the Disease (PGA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for ankylosing spondylitis patients and Disease Activity Score (DAS 28) for rheumatoid arthritis patients) were used for assessment of disease activity. Patients with active chronic inflammatory joint disease were introduced into the infliximab therapy programme.


RESULTS
Infliximab effects were evaluated after 6 weeks of treatment as changes in the quantity of lipid peroxidation products, protein carbonyl groups, reduced glutathione content, glutathione peroxidase, catalase and superoxide dismutase.


CONCLUSIONS
Our results revealed that: (i) infliximab has antioxidative properties, (ii) chronic inflammatory joint patients show high levels of oxidative injury, and (iii) oxidative stress is more intense in active disease group than in the inactive disease group.
Túnez
I
I
Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Cordoba, Cordoba, Spain. fm2tufii@uco.es
Feijóo
M
M
Huerta
G
G
Montilla
P
P
Muñoz
E
E
Ruíz
A
A
Collantes
E
E
D000328:Adult; D000465:Algorithms; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D001168:Arthritis / Q000097:blood / Q000188:drug therapy*; D001799:Blood Sedimentation / Q000187:drug effects; D002374:Catalase / Q000097:blood; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D005978:Glutathione / Q000097:blood; D005979:Glutathione Peroxidase / Q000097:blood / Q000378:metabolism; D006801:Humans; D000069285:Infliximab; D007592:Joint Diseases / Q000097:blood / Q000188:drug therapy*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D050050:Protein Carbonylation / Q000187:drug effects; D013482:Superoxide Dismutase / Q000097:blood / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005978:Glutathione